Roche Holding AG (SWX: ROG)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 200.18B |
| Revenue (ttm) | 60.58B |
| Net Income (ttm) | 10.62B |
| Shares Out | 796.79M |
| EPS (ttm) | 13.24 |
| PE Ratio | 18.83 |
| Forward PE | 12.77 |
| Dividend | 9.60 (3.85%) |
| Ex-Dividend Date | n/a |
| Volume | 308,419 |
| Open | 248.40 |
| Previous Close | 249.20 |
| Day's Range | 248.30 - 250.70 |
| 52-Week Range | 212.90 - 288.20 |
| Beta | 0.15 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 31, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, d... [Read more]
Financial Performance
In 2023, Roche Holding AG's revenue was 60.44 billion, a decrease of -8.16% compared to the previous year's 65.81 billion. Earnings were 11.50 billion, a decrease of -7.43%.
Financial StatementsNews
Roche Canada Announces New Informatics Jobs in Ontario's Life Sciences Sector
These jobs will propel the province towards being a global leader in biomanufacturing and life sciences MISSISSAUGA, ON , Nov. 19, 2024 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to a...
Neuron23 Announces Usage of Roche's Digital Biomarker and Device in Parkinson's Disease Clinical Trial
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #LRRK2--Neuron23 is using a Roche-developed digital biomarker as the primary endpoint in the Phase 2 NEULARK trial of NEU-411 in early Parkinson's diseas...
Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE
The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay detects the folate receptor 1 protein (FOLR1 or FRɑ), which is over-expressed in most ovarian cancers. The test identifies ovarian cancer patients eligible for...
Roche CEO confident in breakthrough Alzheimer’s drug despite past failures
Roche Holding AG is extremely optimistic that its latest experimental Alzheimer’s drug will deliver a benefit for patients, Chief Executive Officer Thomas Schinecker said, despite a track record of fa...
Flare Therapeutics Inc., a GordonMD® Global Investments LP Portfolio Company, Enters Strategic Discovery Collaboration with Roche
BEVERLY HILLS, Calif.--(BUSINESS WIRE)--GordonMD® Global Investments LP announced today that its portfolio company, Flare Therapeutics Inc., has entered into a strategic discovery collaboration with R...
Immunology Biosimilars Market Research 2024-2030, Profiles of Key Players - F. Hoffmann-La Roche, Merck, Eli Lily,.
Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Immunology Biosimilars Market (2024 Edition): Analysis By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel, By...
Flare Therapeutics collaborates with Roche for discovery of small molecule drugs
Flare Therapeutics partners with Roche in a $70 million deal for novel oncology drugs, milestone payments exceeding $1.8 billion, and royalties on future...
Flare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology
Collaboration will leverage Flare Therapeutics' proteomic and mass spectrometry platform and expertise, powered by its proprietary library of electrophilic compounds, to discover novel small molecules...
Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments
– Net product revenues for the third quarter 2024 totaled $429.8 million, a 39% increase over the same quarter of the prior year – ELEVIDYS net product revenue for the quarter totaled $181.0 million; ...
Health groups join patent war over spinal muscular atrophy drug
Public health groups are challenging Roche's attempt to block a generic version of its expensive Spinal Muscular Atrophy drug, Risdiplam. They argue that Roche's patent infringement lawsuit against Na...
Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024
Basel, 05 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) An...
Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorder...
PredicineCARE™ Liquid Biopsy Assay Featured in NEJM as Pivotal Tool in Roche's Phase III Itovebi Breast Cancer Trial
PredicineCARE™ was utilized to identify and enroll patients with PIK3CA-mutated metastatic breast cancer in China, a key component contributing to the FDA's approval of Inavolisib in the U.S. on Octob...
Antibody-Drug Conjugates (ADC) Technology Research and Global Markets Report 2024-2025 & 2029 with Profiles of Leading Players - F. Hoffmann-La Roche.
Dublin, Nov. 04, 2024 (GLOBE NEWSWIRE) -- The "Antibody-Drug Conjugates: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
Roche Holding AG (RHHBY) Virtual Neurology Investor Event Conference Transcript
Roche Holding AG (OTCQX:RHHBY) Virtual Neurology Investor Event Conference October 31, 2024 11:00 AM ETCompany ParticipantsBruno Eschli – Investor...
Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer's disease
Basel, 31 October 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new late-breaking data on its Elecsys Amyloid Plasma Panel (combination of pTau181 and ApoE4) , for Alzheimer's disease, at ...
New England Journal of Medicine publishes landmark phase III results for Roche's Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer
Basel, 31 October 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of the positive phase III INAVO120 results, evaluating ItovebiTM (inavolisib) in combination with p...
New England Journal of Medicine Publishes Landmark Phase III Results for Genentech's Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast Cancer
– Itovebi TM (inavolisib)-based regimen demonstrated a statistically significant and clinically meaningful benefit, reducing the risk of disease worsening or death by 57% compared with palbociclib and...
New England Journal of Medicine Publishes Landmark Phase III Results for Genentech's Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the positive Phase III INAVO120 results, ...
Roche Discloses Patient Death in Alzheimer’s Trial
An elderly patient died in a clinical study of Roche Holding AG’s experimental treatment for Alzheimer’s disease, prompting changes to the trial design, although the company said overall results suppo...
Roche: Currency Headwinds Are Masking Strong Growth Trends
Roche's key products like Vabysmo, Ocrevus, and Phesgo are performing well. Read why RHHBY stock looks well positioned to deliver long-term shareholder value.
Laboratory Corp Q3 Earnings Beat Street View, Investors Overlook Hurricane Helene Impact
Thursday, Laboratory Corp (NYSE: LH) reported third-quarter 2024 adjusted earnings per share of $3.50, up from $3.38 a year ago, beating the consensus of $3.49 . Sales increased 7.4% year-over-year t...
Roche CEO says there is strong underlying growth in our business
Roche CEO Thomas Schinecker joins Squawk Box after the pharma group's third-quarter sales rose 9%.
Dyno Therapeutics Forms New Strategic Partnership With Roche To Advance AAV Gene Therapy Vectors For Neurological Diseases
WATERTOWN, Mass.--(BUSINESS WIRE)--New strategic partnership leverages the power of Dyno's platform, enabling Roche to advance next-generation AAV gene therapies across multiple targets.
Roche CEO: We can see the strong underlying growth we have in our business
Roche CEO Thomas Schinecker joins Squawk Box after the pharma group's third-quarter sales rose 9%.